Baird raised the firm’s price target on Castle Biosciences (CSTL) to $37 from $36 and keeps an Outperform rating on the shares. The firm updated its model following solid Q4 results.
Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on CSTL:
- Castle Biosciences: Strong Growth Potential and Robust Performance Justify Buy Rating
- Castle Biosciences Reports Strong 2024 Financial Results
- Castle Biosciences Reports Strong 2024 Financial Performance
- Castle Biosciences reports Q4 EPS 32c, consensus 4c
- Castle Biosciences sees FY25 revenue $280M-$295M, consensus $269.06M